Update on 2 Gene Therapy Trials for Rare Eye Diseases – Rare Disease Report
|
Update on 2 Gene Therapy Trials for Rare Eye Diseases
Rare Disease Report The company also announced it has completed dosing of the second cohort of its Phase 1/2 gene therapy trial in patients with Leber's congential amaurosis. The purpose of this study is to determine if subretinal administroin of the AVV gene therapy is safe. MeiraGTx Provides Clinical Trial Updates for Achromatopsia and Leber's Congenital Amaurosis Ocular Gene Therapy … |
